Clinical Trial Update: Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating radiotherapy combined with Anlotinib for HER2-negative breast cancer with brain metastases; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Breast Cancer

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: HER2-Negative Breast Cancer | Phase 2 | Status: RECRUITING